NIH Center Sets New Goals for Global Health Research and Training
Global health research and training efforts should focus on combatting the growing epidemic of noncommunicable diseases, better incorporating information technology into research and training, and more effectively converting scientific discoveries into practice in low-resource settings, according to the Fogarty International Center’s new strategic plan, released today. Fogarty is the component of the National Institutes of Health solely focused on supporting global health research and training, and coordinating international research partnerships across the agency.
As research discoveries and aid efforts have reduced deaths from HIV/AIDS, populations in the developing world are increasingly suffering from noncommunicable diseases such as heart disease, cancer, diabetes, and mental illness.
“It is critical that we leverage the existing HIV research and care delivery platform to build the capacity needed to stem the tide of these new disease epidemics,” said Dr Roger I. Glass, who leads Fogarty and serves as the NIH associate director for global health research. “We must focus our attention on these pressing problems, which also plague us in the US, and discover new ways to prevent and treat them. Today, global health and local health are becoming one and the same and research anywhere can help people everywhere.”
Fogarty plans to reinvigorate its efforts to train more developing-country scientists in these new areas of global health, where the field is moving and where the most interesting discoveries are yet to be made, according to the plan.
“Our concept of investing in training outstanding young investigators, both US and foreign, and linking them early in their careers in research partnerships between their institutions has been a winning strategy that has had a major impact on the research enterprise for global engagement,” said Glass.
To read more, click here.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.